BIOLOGICAL MARKERS FOR PREDICTING RESPONSIVENESS TO IBRUTINIB AND R-CHOP COMBINATION THERAPY AND METHODS OF USING THE SAME

摘要

Disclosed herein are biological markers useful in identifying and treating patients with diffuse large B-cell lymphoma. Provided are methods of predicting a likelihood of responsiveness to ibrutinib and R-CHOP combination therapy in a patient having diffuse large B-cell lymphoma, methods of treating a patient having diffuse large B-cell lymphoma, and methods of identifying a patient as having diffuse large B-cell lymphoma.